Results

Exela Technologies Announces 1 for 20 Reverse Stock Split

Exela Technologies, Inc. Reports Preliminary Second Quarter 2022 Results

Exela Technologies, Inc. Revenue of $267 million, a decline of 9% from Q2 2021 Net loss of $79 million $230 million of TCV(1) won, a 294% increase compared to Q1 2022 Small-and-Medium-Sized Business (“SMB”) continues strong growth with DMR(2) customers growing 343% over Q2 2021 and DrySign® users growing 1,786% over Q2 2021 Total debt(3) …

Exela Technologies, Inc. Reports Preliminary Second Quarter 2022 Results Read More »

Lemonade Announces Second Quarter 2022 Financial Results

Lemonade Announces Second Quarter 2022 Financial Results

NEW YORK, August 08, 2022–(BUSINESS WIRE)–Lemonade, Inc. (NYSE: LMND) has released its second quarter 2022 financial results by posting them to its website. Please view the Q2 2022 financial results in the Letter to Shareholders on the company’s investor relations website. On Tuesday, August 9, 2022, Lemonade will host a conference call at 8:00 a.m. …

Lemonade Announces Second Quarter 2022 Financial Results Read More »

NVIDIA Announces Preliminary Financial Results for Second Quarter Fiscal 2023

NVIDIA Announces Preliminary Financial Results for Second Quarter Fiscal 2023

Preliminary second quarter revenue of $6.70 billion versus outlook of $8.10 billion Shortfall versus outlook primarily driven by weaker Gaming revenue Management to discuss financial results and outlook on Aug. 24 earnings call NVIDIA (NASDAQ: NVDA) today announced selected preliminary financial results for the second quarter ended July 31, 2022. Second …

NVIDIA Announces Preliminary Financial Results for Second Quarter Fiscal 2023 Read More »

Virgin Galactic Announces Second Quarter 2022 Financial Results And Provides Business Update

Advancement of Strategic Initiatives Positions the Company for Scaled Growth Selected Aurora Flight Sciences, a Boeing Subsidiary, to Build Two New Motherships; First Next-Generation Mothership Planned to Enter Service in 2025 Delta Class Spaceship Manufacturing Facility in Phoenix Area, Expected to be Fully Operational in Late 2023 Commercial Launch Anticipated for Q2 2023 TUSTIN, Calif.–(BUSINESS …

Virgin Galactic Announces Second Quarter 2022 Financial Results And Provides Business Update Read More »

Intel's 'Inexcusable' Earnings Show It Can't Forecast Its Own Results Says Analyst

Intel’s ‘Inexcusable’ Earnings Show It Can’t Forecast Its Own Results Says Analyst

This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy. After it released its earnings report for the second quarter of the fiscal year 2022 earlier this week, chip maker Intel Corporation is the subject of some hard hitting analyst coverage from …

Intel’s ‘Inexcusable’ Earnings Show It Can’t Forecast Its Own Results Says Analyst Read More »

Mott Capital Management profile picture

Alphabet Shares Face A Steep Drop Following Q2 Results (NASDAQ:GOOG)

JHVEPhoto This story was originally published for subscribers of Reading The Markets an SA Marketplace service, on July 22. It has been updated as of the afternoon of July 25. Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL) shares have fallen sharply following disappointing results from Snap (SNAP) on July 21. Snap sent a shockwave through the social media and …

Alphabet Shares Face A Steep Drop Following Q2 Results (NASDAQ:GOOG) Read More »

VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B

VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B

PH94B for Acute Treatment of Social Anxiety Disorder Did Not Meet Primary Endpoint PH94B Showed a Favorable Safety and Tolerability Profile among Study Participants that was Consistent with Prior Clinical Trial Results SOUTH SAN FRANCISCO, Calif., July 22, 2022–(BUSINESS WIRE)–VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen, the Company), a late clinical-stage biopharmaceutical company aiming to transform …

VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B Read More »

UPDATE -- NIO Inc. Reports Unaudited First Quarter 2022 Financial Results

Cleveland-Cliffs Reports Second-Quarter 2022 Results

Second-quarter revenue of $6.3 billion Second-quarter net income of $601 million Second-quarter Adjusted EBITDA1 of $1.1 billion CLEVELAND, July 22, 2022–(BUSINESS WIRE)–Cleveland-Cliffs Inc. (NYSE: CLF) today reported second-quarter results for the period ended June 30, 2022. Second-quarter 2022 consolidated revenues were $6.3 billion, compared to the prior-year second-quarter revenues of $5.0 billion. For the second …

Cleveland-Cliffs Reports Second-Quarter 2022 Results Read More »